腹主动脉瘤腔内隔绝术五年商用现状解读
本文综述Nellix系统行腔内动脉瘤封堵术(EVAS)商用五年来的证据,指出前瞻性多中心试验显示1年随访I型内漏和再干预率低,与传统EVAR相当,II型内漏罕见,但耐久性尚待证实。
要点
- EVAS术后1年I型内漏和再干预率低,与传统EVAR相当
- 主动瘤囊管理使II型内漏罕见,并可能减少植入后综合征和心脏并发症
- EVAS后颈动脉扩张较EVAR少,但耐久性仍需前瞻性研究证实
核心结论
- EVAS商用五年证据显示1年随访I型内漏和再干预率低,与当代EVAR相当,但耐久性尚未证实。
研究设计与样本
- 本文为综述,分析EVAS商用五年来的当前证据,涵盖前瞻性多中心试验结果。
主要发现
- 前瞻性多中心试验显示EVAS术后1年I型内漏和再干预发生率低,与使用现代器械的传统EVAR相当。
- EVAS主动管理瘤囊使II型内漏罕见,并观察到植入后综合征和心脏并发症发生率降低,1年全因死亡率低。
- 与EVAR相比,EVAS后颈动脉扩张较少。
- 已识别迁移和近端内漏等并发症并制定治疗策略,但耐久性仍需证实。
临床怎么用
- EVAS可用于腹主动脉瘤管理,但需认识其并发症并掌握治疗策略。
- EVAS的主动瘤囊管理可能带来减少II型内漏等获益,但耐久性待证实,需进一步前瞻性研究。
局限性
- 耐久性尚未证实,需进一步前瞻性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Endovascular aneurysm sealing (EVAS) using the Nellix Endovascular Sealing System was introduced commercially in 2013 with the aim of reducing the incidences of reintervention and late complications observed after conventional endovascular aneurysm repair (EVAR). In the 5 years since its commercial launch, the Nellix system has evolved in terms of its structure, instructions for use, and delivery technique. Complications, including migration and proximal endoleak, have been recognized and treatment strategies developed, although durability remains to be demonstrated. Prospective multicenter trials have shown a low incidence of type I endoleak and reintervention at 1-year follow-up, comparable to conventional EVAR with modern devices. Since the aneurysm sac is "actively managed" with EVAS, similar to open surgical repair, type II endoleaks are rare with the Nellix system. Unexpected benefits of active sac management with EVAS include reduced incidences of postimplantation syndrome and cardiac complications, with low all-cause mortality at 1 year. Less neck dilatation compared to EVAR has also been observed. The Nellix device and procedure continue to evolve, and further prospective studies are indicated. This article analyzes the current EVAS evidence to update our knowledge of this technique in the management of abdominal aortic aneurysm.
引用
- Reijnen MMPJ, Holden A. Status of Endovascular Aneurysm Sealing After 5 Years of Commercial Use. J Endovasc Ther. 2018. PMID: 29380655. doi:10.1177/1526602818755484
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。